Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emily C. Atkinson

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient With Lung Adenocarcinoma Following Treatment With Erlotinib and Osimertinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Growth and Nutrition in Children With Trichothiodystrophy

Journal of Pediatric Gastroenterology and Nutrition
Child HealthPediatricsPerinatologyGastroenterology
2014English

Related publications

P3.cr-09 MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma" With "MET Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Letter to Editor Recovery From Paraplegia With Administration of Erlotinib in a Patient With Lung Adenocarcinoma

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2014English

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-Small Cell Lung Cancer With the EGFR T790M Mutation, Detected From Circulating Tumor DNA: LiquidLung-O-Cohort 2

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient With MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Successful Rechallenge With Reduced Dose of Erlotinib in a Patient With Lung Adenocarcinoma Who Developed Erlotinib‑associated Leukocytoclastic Vasculitis: A Case Report

Oncology Letters
Cancer ResearchOncology
2012English

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma With G719S, S768I, and T790M Mutations

Internal Medicine
Internal MedicineMedicine
2018English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy